Compare Abbott Laboratories (ABT) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs HP Inc — how do they compare? Abbott Laboratories trades at $111.04 (market cap $187.95B), while HP Inc trades at $28.75 (market cap $26.59B). The key difference: Abbott Laboratories is far larger — about 7.1× HP Inc's market cap, and HP Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| ABT | HPQ | |
|---|---|---|
Market Cap | $187.95B | $26.59B |
Sector | Health | Technology |
52-Week High | $136.62 | $30.05 |
52-Week Low | $82.57 | $18.20 |
Enterprise Value | $214.96B | $33.75B |
Dividend Yield | 2.32% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
HPQ trades at $28.72, down 3.62% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $55.3B in 2025, though net margins compressed to 4.45%. The stock offers a dividend yield near 4% and trades at attractive valuations with a P/E of 10.77 and P/S of 0.48. Recent news highlights AI-driven cost savings and a potential 2027 upgrade cycle, while institutional activity shows mixed positioning adjustments.
Outlook: HPQ presents value with low multiples and dividend income, but faces PC market volatility and margin pressure. Risks include competitive threats and debt levels, while catalysts include AI product adoption. Analyst consensus is mixed with a hold rating, but technical strength and earnings consistency support cautious optimism for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
